Informative/JJ
Gene/NN
Selection/NN
Method/NN
in/IN
Tumor/NN
Classification/NN
./.
====================
Gene/NN
expression/NN
profiles/NNS
may/MD
offer/VB
more/RBR
information/NN
than/IN
morphology/NN
and/CC
provide/VBP
an/DT
alternative/JJ
to/TO
morphology-/VB
based/VBN
tumor/NN
classification/NN
systems/NNS
./.
====================
Informative/JJ
gene/NN
selection/NN
is/VBZ
finding/NN
gene/NN
subsets/NNS
that/DT
are/VBP
able/JJ
to/TO
discriminate/VB
between/IN
tumor/NN
types/NNS
,/,
and/CC
may/MD
have/VB
clear/JJ
biological/JJ
interpretation/NN
./.
====================
Gene/NN
selection/NN
is/VBZ
a/DT
fundamental/JJ
issue/NN
in/IN
gene/NN
expression/NN
based/VBN
tumor/NN
classification/NN
./.
====================
In/IN
this/DT
report/NN
,/,
techniques/NNS
for/IN
selecting/VBG
informative/JJ
genes/NNS
are/VBP
illustrated/VBN
and/CC
supervised/VBD
shaving/VBG
introduced/VBN
as/IN
a/DT
gene/NN
selection/NN
method/NN
in/IN
the/DT
place/NN
of/IN
a/DT
clustering/NN
algorithm/NN
./.
====================
The/DT
supervised/VBN
shaving/VBG
method/NN
showed/VBD
good/JJ
performance/NN
in/IN
gene/NN
selection/NN
and/CC
classification/NN
,/,
even/RB
though/IN
it/PRP
is/VBZ
a/DT
clustering/NN
algorithm/NN
./.
====================
Almost/RB
selected/VBN
genes/NNS
are/VBP
related/JJ
to/TO
leukemia/NN
disease/NN
./.
====================
The/DT
expression/NN
profiles/NNS
of/IN
3051/CD
genes/NNS
were/VBD
analyzed/VBN
in/IN
27/CD
acute/JJ
lymphoblastic/JJ
leukemia/NN
and/CC
11/CD
myeloid/JJ
leukemia/NN
samples/NNS
./.
====================
Through/IN
these/DT
examples/NNS
,/,
the/DT
supervised/VBN
shaving/VBG
method/NN
has/VBZ
been/VBN
shown/VBN
to/TO
produce/VB
biologically/RB
significant/JJ
genes/NNS
of/IN
more/RBR
than/IN
94/CD
%/NN
accuracy/NN
of/IN
classification/NN
./.
====================
In/IN
this/DT
report/NN
,/,
SVM/NN
has/VBZ
also/RB
been/VBN
shown/VBN
to/TO
be/VB
a/DT
practicable/JJ
method/NN
for/IN
gene/NN
expression-based/VBD
classification/NN
./.
====================
DNA/NN
microarray/NN
technology/NN
generated/VBN
a/DT
panoramic/JJ
survey/NN
of/IN
genes/NNS
expressed/VBN
in/IN
a/DT
sample/JJ
of/IN
cells/NNS
./.
====================
When/WRB
the/DT
samples/NNS
correspond/VBP
to/TO
different/JJ
pathological/JJ
states/NNS
of/IN
the/DT
same/JJ
tissue/NN
or/CC
subtypes/NNS
of/IN
the/DT
sample/JJ
malignancy/NN
,/,
transcription/NN
profiling/VBG
holds/NNS
promise/VBP
as/IN
a/DT
method/NN
for/IN
classifying/VBG
and/CC
analyzing/VBG
cancer/NN
from/IN
a/DT
molecular/JJ
rather/RB
====================
than/IN
morphological/JJ
perspective/JJ
(/(
Alizadeh/NN
et/FW
at/IN
./.
====================
,/,
2000/CD
,/,
Alon/NN
et/FW
al/JJ
„/CD
1999/CD
)/)
./.
====================
Several/JJ
studies/NNS
have/VBP
used/VBN
arrays/NNS
to/TO
analyze/VB
gene/NN
expression/NN
in/IN
the/DT
colon/NN
,/,
breast/NN
and/CC
other/JJ
tumors/NNS
,/,
and/CC
these/DT
studies/NNS
have/VBP
demonstrated/VBN
the/DT
potential/JJ
utility/NN
of/IN
expression/NN
profiling/VBG
for/IN
classifying/VBG
tumors/NNS
(/(
Perou/NNP
et/FW
a/DT
!/JJ
./.
,/,
1999/CD
)/)
./.
====================
Informative/JJ
Gene/NN
selection/NN
is/VBZ
an/DT
important/JJ
component/NN
for/IN
gene/NN
expressiorrbased/VBD
tumor/NN
classification/NN
systems/NNS
./.
====================
A/DT
large/JJ
numbers/NNS
of/IN
genes/NNS
increase/VBP
the/DT
computational/JJ
complexity/NN
and/CC
cost/JJ
,/,
and/CC
compromise/VB
the/DT
generalization/NN
properties/NNS
of/IN
the/DT
classifier/NN
./.
====================
It/PRP
is/VBZ
recognized/VBN
that/DT
the/DT
higher/JJR
the/DT
ratio/NN
of/IN
the/DT
number/NN
of/IN
training/VBG
samples/NNS
to/TO
the/DT
number/NN
of/IN
free/JJ
classifier/NN
parameters/NNS
,/,
the/DT
better/RBR
the/DT
generalization/NN
properties/NNS
of/IN
the/DT
resulting/VBG
classifier/NN
./.
====================
A/DT
large/JJ
number/NN
of/IN
genes/NNS
will/MD
improve/VB
the/DT
estimation/NN
of/IN
the/DT
classification/NN
error/NN
./.
====================
Therefore/RB
,/,
reducing/VBG
the/DT
dimensionality/NN
of/IN
the/DT
gene/NN
expression/NN
information/NN
is/VBZ
a/DT
key/JJ
issue/NN
in/IN
developing/VBG
a/DT
successful/JJ
gene/NN
expressiorrbased/VBD
tumor/NN
classification/NN
system/NN
./.
====================
In/IN
addition/NN
to/TO
reducing/VBG
noise/RB
and/CC
improving/VBG
the/DT
accuracy/NN
of/IN
tumor/NN
classification/NN
,/,
a/DT
selected/VBN
subset/NN
of/IN
genes/NNS
,/,
with/IN
high/JJ
accuracy/NN
of/IN
classification/NN
,/,
may/MD
be/VB
involved/VBN
in/IN
the/DT
pathways/NNS
or/CC
some/DT
biological/JJ
process/NN
leading/VBG
to/TO
tumor/NN
development/NN
and/CC
have/VBP
important/JJ
biological/JJ
meaning/VBG
./.
====================
That/DT
is/VBZ
,/,
these/DT
informative/JJ
genes/NNS
represent/VBP
putative/JJ
targets/NNS
for/IN
therapeutic/JJ
agents/NNS
and/CC
understanding/NN
the/DT
basic/JJ
biology/NN
of/IN
the/DT
disorder/NN
./.
====================
A/DT
typical/JJ
profiling/VBG
study/NN
measures/VBZ
the/DT
expression/NN
levels/NNS
of/IN
thousands/NNS
of/IN
genes/NNS
(/(
features/NNS
)/)
L/NN
across/IN
tens/NNS
of/IN
samples/NNS
N/NN
,/,
with/IN
each/DT
samples/NNS
labeled/VBN
as/IN
being/VBG
of/IN
one/CD
type/NN
or/CC
another/DT
./.
====================
The/DT
problem/NN
to/TO
be/VB
considered/VBN
here/RB
is/VBZ
that/DT
of/IN
identifying/VBG
marker/NN
genes/NNS
given/VBN
N/NN
labeled/VBN
L-features/NNS
samples/NNS
./.
====================
The/DT
method/NN
introduced/VBN
by/IN
Golub/NN
et/FW
al/JJ
,/,
(/(
1999/CD
)/)
was/VBD
examined/VBN
to/TO
focus/VB
the/DT
selection/NN
of/IN
genes/NNS
that/WDT
appear/VBP
to/TO
be/VB
the/DT
best/JJS
diagnostic/JJ
indicators/NNS
./.
====================
This/DT
amounts/NNS
to/TO
kind/VB
of/IN
dimensionality/NN
reduction/NN
of/IN
the/DT
dataset/NN
,/,
and/CC
shows/VBZ
good/JJ
performance/NN
in/IN
tumor/NN
type/NN
classification/NN
./.
====================
However/RB
,/,
the/DT
subset/NN
genes/NNS
were/VBD
found/VBN
not/RB
to/TO
correlate/VB
with/IN
each/DT
other/JJ
,/,
and/CC
some/DT
genes/NNS
do/VBP
not/RB
have/VB
a/DT
biological/JJ
meaningful/JJ
explanation/NN
./.
====================
In/IN
order/NN
to/TO
improve/VB
this/DT
gene/NN
selection/NN
method/NN
,/,
additional/JJ
effort/NN
is/VBZ
needed/VBN
to/TO
develop/VB
ways/NNS
of/IN
identifying/VBG
meaningful/JJ
genes/NNS
in/IN
these/DT
types/NNS
of/IN
dataset/NN
./.
====================
(/(
Furey/JJ
et/FW
a/DT
!/JJ
./.
,/,
2000/CD
)/)
====================
In/IN
this/DT
report/NN
,/,
we/PRP
propose/VBP
‘/IN
supervised/VBD
shaving/VBG
’/CD
clustering/NN
analysis/NN
of/IN
gene/NN
expression/NN
data/NNS
is/VBZ
proposed/VBN
for/IN
the/DT
identification/NN
of/IN
gene/NN
subsets/NNS
./.
====================
The/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
is/VBZ
designed/VBN
to/TO
extract/NN
coherent/JJ
and/CC
small/JJ
clusters/NNS
of/IN
genes/NNS
that/WDT
vary/VBP
as/IN
much/RB
as/IN
possible/JJ
across/IN
the/DT
====================
samples/NNS
./.
====================
In/IN
addition/NN
,/,
supervised/VBD
shaving/VBG
is/VBZ
proposed/VBN
via/IN
the/DT
incorporation/NN
of/IN
other/JJ
prognostic/JJ
factors/NNS
in/IN
the/DT
search/NN
for/IN
interesting/JJ
gene/NN
clusters/NNS
(/(
Hastie/NNP
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
As/IN
a/DT
result/NN
of/IN
‘/NN
supervised/VBD
shaving/VBG
’/CD
as/IN
a/DT
gene/NN
selection/NN
method/NN
,/,
more/RBR
biologically/RB
meaningful/JJ
subsets/NNS
of/IN
genes/NNS
were/VBD
obtained/VBN
in/IN
a/DT
cluster/NN
./.
====================
The/DT
gene/NN
selection/NN
issue/NN
has/VBZ
been/VBN
addressed/VBN
under/IN
a/DT
classification/NN
framework/NN
that/DT
may/MD
be/VB
more/RBR
relevant/JJ
to/TO
the/DT
clinical/JJ
application/NN
in/IN
a/DT
diagnosis/NN
./.
====================
To/TO
this/DT
end/NN
,/,
the/DT
use/NN
of/IN
SVM/NN
has/VBZ
been/VBN
present/JJ
,/,
as/IN
a/DT
supervised/VBN
machine/NN
learning/VBG
technique/NN
,/,
for/IN
the/DT
classification/NN
algorithms/NNS
./.
====================
SVMs/NNS
have/VBP
been/VBN
shown/VBN
to/TO
perform/VB
well/RB
in/IN
multiple/JJ
areas/NNS
of/IN
biological/JJ
analysis/NN
,/,
including/VBG
evaluating/VBG
microarray/NN
expression/NN
data/NNS
(/(
Brown/JJ
et/FW
a/DT
!/JJ
./.
,/,
2000/CD
)/)
./.
====================
SVMs/NNS
have/VBP
demonstrated/VBN
the/DT
ability/NN
to/TO
not/RB
only/RB
correctly/RB
separate/JJ
entities/VBZ
into/IN
appropriate/JJ
classes/NNS
,/,
but/CC
also/RB
identify/VBP
instances/NNS
whose/WP$
established/JJ
classification/NN
is/VBZ
not/RB
supported/VBN
by/IN
the/DT
data/NNS
./.
====================
Expression/NN
datasets/NNS
contain/VBP
measurements/NNS
for/IN
thousands/NNS
of/IN
genes/NNS
,/,
which/WDT
prove/VBP
problematic/JJ
for/IN
many/JJ
traditional/JJ
methods/NNS
./.
====================
SVMs/NNS
are/VBP
well/RB
suited/VBN
to/TO
working/VBG
with/IN
high/JJ
dimensional/JJ
data/NNS
such/JJ
as/IN
this/DT
./.
====================
To/TO
test/VB
the/DT
generality/NN
of/IN
the/DT
approach/NN
,/,
experiments/NNS
were/VBD
run/JJ
using/VBG
the/DT
leukemia/NN
data/NNS
from/IN
Golub/NN
et/FW
at/IN
./.
====================
(/(
1999/CD
)/)
(/(
72/CD
patient/NN
samples/NNS
)/)
./.
====================
Clustered/JJ
genes/NNS
,/,
due/JJ
to/TO
PCA/NN
based/VBN
‘/CD
supervised/VBD
shaving/VBG
’/CD
were/VBD
shown/VBN
to/TO
achieve/VB
high/JJ
accuracy/NN
of/IN
classification/NN
,/,
and/CC
that/IN
the/DT
selected/VBN
genes/NNS
can/MD
be/VB
used/VBN
as/IN
biomarkers/NNS
for/IN
tumor/NN
classification/NN
./.
====================
A/DT
data/NNS
set/VBP
,/,
well/RB
known/VBN
for/IN
human/JJ
acute/JJ
leukemia/NN
samples/NNS
,/,
originally/RB
analyzed/VBD
by/IN
Golub/NN
et/FW
at/IN
./.
====================
was/VBD
used/VBN
./.
====================
The/DT
raw/NN
dataset/NN
can/MD
be/VB
obtained/VBN
at/IN
:/:
http/NN
:/:
//www.broad.mit.edu//JJ
cgi-bin/cancer//JJ
datasets.cgi/NNS
./.
====================
The/DT
dataset/NN
consisted/VBD
of/IN
the/DT
expression/NN
profiles/NNS
of/IN
6817/CD
genes/NNS
from/IN
47/CD
ALL/NN
and/CC
25/CD
AML/NN
samples/NNS
./.
====================
The/DT
first/JJ
step/NN
in/IN
out/RP
process/NN
of/IN
analyzing/VBG
these/DT
data/NNS
was/VBD
to/TO
perform/VB
the/DT
basic/JJ
transformations/NNS
reported/VBD
in/IN
Golub/NN
1999/CD
./.
====================
The/DT
transformations/NNS
set/NN
the/DT
minimum/JJ
expression/NN
values/NNS
to/TO
100/CD
and/CC
the/DT
maximum/NN
to/TO
16000/CD
,/,
and/CC
then/RB
the/DT
genes/NNS
that/WDT
are/VBP
beyond/VBN
these/DT
limits/NNS
are/VBP
filtered/VBN
out/RP
./.
====================
The/DT
====================
filtering/VBG
process/NN
selected/VBN
3051/CD
genes/NNS
that/WDT
seemed/VBD
worthy/NN
of/IN
further/JJ
investigation/NN
./.
====================
The/DT
filtering/JJ
was/VBD
not/RB
especially/RB
robust/JJ
,/,
in/IN
the/DT
sense/NN
that/DT
it/PRP
was/VBD
based/VBN
on/IN
the/DT
minimum/JJ
or/CC
maximum/JJ
expression/NN
values/NNS
between/IN
subjects/NNS
./.
====================
This/DT
was/VBD
a/DT
non-specific/JJ
filter/NN
./.
====================
The/DT
genes/NNS
were/VBD
selected/VBN
according/VBG
to/TO
their/PRP$
variability/NN
,/,
and/CC
not/RB
with/IN
respect/NN
to/TO
their/PRP$
ability/NN
to/TO
classify/VB
any/DT
particular/JJ
set/NN
of/IN
samples/NNS
./.
====================
In/IN
this/DT
analysis/NN
,/,
the/DT
genes/NNS
were/VBD
selected/VBN
according/VBG
to/TO
their/PRP$
behavior/NN
in/IN
the/DT
training/VBG
set/NN
./.
====================
If/IN
the/DT
same/JJ
gene/NN
selection/NN
methods/NNS
were/VBD
applied/VBN
to/TO
the/DT
test/NN
set/NN
,/,
a/DT
different/JJ
set/NN
of/IN
genes/NNS
would/MD
be/VB
selected/VBN
in/IN
the/DT
test/NN
set/NN
,/,
despite/IN
the/DT
identical/JJ
selection/NN
process/NN
./.
====================
Due/IN
to/TO
the/DT
need/NN
to/TO
compare/VB
and/CC
combine/VBP
the/DT
analyses/NNS
that/IN
approach/VBP
could/MD
not/RB
be/VB
used/VBN
:/:
the/DT
same/JJ
genes/NNS
,/,
not/RB
just/RB
the/DT
same/JJ
filters/NNS
,/,
must/MD
be/VB
employed/VBN
in/IN
both/DT
phases/NNS
of/IN
the/DT
analysis/NN
./.
====================
Permutation/NN
adjusted/VBN
p-values/NNS
for/IN
the/DT
maxT/JJ
procedure/NN
,/,
with/IN
Welch/JJ
t-statistics/NNS
,/,
were/VBD
computed/VBN
./.
====================
The/DT
adjusted/JJ
p-values/NNS
for/IN
the/DT
maxT/JJ
and/CC
minP/NN
step-down/JJ
multiple/JJ
testing/VBG
procedures/NNS
are/VBP
described/VBN
in/IN
Westfall/JJ
and/CC
Young/NN
(/(
1993/CD
)/)
./.
====================
The/DT
bioconductor/NN
’/CD
s/NNS
multitest/JJS
packages/NNS
were/VBD
used/VBN
,/,
which/WDT
contain/VBP
a/DT
collection/NN
of/IN
functions/NNS
for/IN
multiple/JJ
====================
hypotheses/NNS
testing/NN
,/,
implemented/VBD
using/VBG
R/NN
language/NN
./.
====================
These/DT
functions/NNS
can/MD
be/VB
used/VBN
to/TO
identify/VB
differentially/RB
expressed/VBN
genes/NNS
in/IN
microarray/NN
experiments/NNS
,/,
that/DT
is/VBZ
,/,
genes/NNS
whose/WP$
expression/NN
levels/NNS
are/VBP
associated/VBN
with/IN
a/DT
response/NN
or/CC
covariate/VB
of/IN
interest/NN
./.
====================
The/DT
17/CD
genes/NNS
with/IN
the/DT
smallest/JJS
adjusted/VBN
p-value/NN
were/VBD
selected/VBN
for/IN
the/DT
classification/NN
analysis/NN
./.
====================
Golub/NN
et/FW
al/JJ
./.
====================
proposed/VBN
the/DT
use/NN
of/IN
a/DT
collection/NN
of/IN
known/VBN
samples/NNS
to/TO
generate/VB
a/DT
“/JJ
class/NN
predictor/NN
”/CD
which/WDT
is/VBZ
then/RB
able/JJ
to/TO
assign/VB
a/DT
new/JJ
sample/NN
to/TO
one/CD
of/IN
two/CD
classes/NNS
./.
====================
This/DT
predictor/NN
is/VBZ
created/VBN
with/IN
the/DT
aid/NN
of/IN
prediction/NN
strength/NN
’/CD
./.
====================
Let/NNP
[/(
/zi/NNP
(/(
p/NN
)/)
,/,
si/NNP
(/(
p/NN
)/)
]/)
and/CC
[/(
^/CD
(/(
p/NN
)/)
,/,
9^g/JJ
)/)
\/CD
denote/JJ
the/DT
means/NNS
and/CC
standard/JJ
deviation/NN
of/IN
the/DT
log/NN
of/IN
the/DT
expression/NN
levels/NNS
of/IN
gene/NN
g/NN
in/IN
two/CD
samples/NNS
,/,
respectively/RB
./.
====================
Then/RB
,/,
PS/NN
is/VBZ
defined/VBN
====================
as/IN
this/DT
./.
====================
W/NN
e/NN
calculate/JJ
PS/NN
scores/VBZ
,/,
which/WDT
give/VBP
the/DT
highest/JJS
score/RB
to/TO
====================
those/DT
genes/NNS
whose/WP$
expression/NN
levels/NNS
,/,
differ/VBP
most/JJS
on/IN
average/NN
in/IN
the/DT
two/CD
classes/NNS
while/IN
also/RB
favoring/VBG
those/DT
with/IN
small/JJ
deviations/NNS
in/IN
scores/NNS
in/IN
the/DT
respective/JJ
classes/NNS
./.
====================
We/PRP
then/RB
simply/RB
take/VBP
the/DT
genes/NNS
with/IN
the/DT
top/NN
17/CD
ranked/VBD
PS/NN
scores/VBZ
as/IN
our/PRP$
top/NN
features/NNS
./.
====================
Gene/NN
shaving/VBG
,/,
introduced/VBD
by/IN
Hastie/NN
et/FW
a/DT
!/JJ
„/CD
is/VBZ
a/DT
method/NN
====================
for/IN
exploratory/JJ
analysis/NN
of/IN
gene/NN
expression/NN
microarray/NN
data/NNS
./.
====================
It/PRP
tries/VBZ
to/TO
identify/VB
subset/NN
of/IN
genes/NNS
with/IN
coherent/JJ
expression/NN
patterns/NNS
with/IN
large/JJ
variation/NN
across/IN
samples/NNS
./.
====================
The/DT
method/NN
differ/VBP
form/VBP
hierarchical/JJ
clustering/NN
method/NN
in/IN
that/DT
genes/NNS
may/MD
belong/VB
to/TO
more/RBR
than/IN
one/CD
cluster/NN
,/,
and/CC
the/DT
clustering/NN
can/MD
be/VB
un-supervised/VBN
,/,
treat/NN
the/DT
genes/NNS
and/CC
samples/NNS
as/IN
unlabeled/JJ
,/,
or/CC
partially/RB
or/CC
fully/RB
supervised/VBD
by/IN
known/VBN
properties/NNS
of/IN
genes/samples/NNS
./.
====================
Gene/NN
shaving/VBG
is/VBZ
an/DT
iterative/JJ
algorithm/NN
based/VBN
on/IN
the/DT
principal/JJ
components/NNS
or/CC
the/DT
singular/JJ
value/NN
decomposition/NN
(/(
SVD/NN
)/)
of/IN
the/DT
data/NNS
matrix/VBP
./.
====================
It/PRP
starts/VBZ
with/IN
the/DT
entire/JJ
microarray/NN
gene/NN
expression/NN
matrix/NN
A/NN
and/CC
seeks/VBZ
a/DT
function/NN
of/IN
the/DT
genes/NNS
in/IN
the/DT
direction/JJ
of/IN
maximal/JJ
variation/NN
across/IN
the/DT
samples/NNS
./.
====================
The/DT
simplest/JJS
form/NN
of/IN
this/DT
function/NN
is/VBZ
a/DT
normalized/JJ
linear/JJ
combination/NN
of/IN
the/DT
genes/NNS
weighted/VBD
by/IN
its/PRP$
largest/JJS
principal/JJ
component/NN
loadings/VBZ
,/,
referred/VBN
to/TO
as/IN
the/DT
super/JJ
gene/NN
./.
====================
The/DT
genes/NNS
may/MD
be/VB
sorted/VBN
according/VBG
to/TO
the/DT
principal/JJ
component/NN
weights/NNS
./.
====================
A/DT
fraction/NN
a/DT
of/IN
the/DT
genes/NNS
having/VBG
lowest/JJS
correlation/NN
(/(
essentially/RB
the/DT
absolute/JJ
inner/JJ
product/NN
)/)
with/IN
the/DT
super/JJ
gene/NN
are/VBP
then/RB
shaved/VBD
off/IN
from/IN
the/DT
original/JJ
data/NNS
matrix/VBP
./.
====================
The/DT
process/NN
of/IN
calculating/JJ
the/DT
leading/VBG
principal/JJ
component/NN
and/CC
shaving/VBG
off/IN
some/DT
genes/NNS
is/VBZ
iterated/VBN
on/IN
the/DT
reduced/VBN
data/NNS
matrix/VBP
until/IN
only/RB
two/CD
genes/NNS
remain/VBP
./.
====================
This/DT
iterative/JJ
to-down/RB
process/NN
produces/VBZ
a/DT
sequence/NN
of/IN
nested/JJ
gene/NN
blocks/VBZ
of/IN
sizes/NNS
ranging/VBG
from/IN
the/DT
full/JJ
set/NN
of/IN
N/NN
genes/NNS
down/RB
to/TO
the/DT
final/JJ
block/VBP
consisting/VBG
of/IN
just/RB
two/CD
genes/NNS
./.
====================
The/DT
method/NN
requires/VBZ
a/DT
quality/NN
measure/VB
for/IN
a/DT
cluster/NN
./.
====================
In/IN
particular/JJ
,/,
a/DT
Gap/JJ
estimation/NN
is/VBZ
used/VBN
to/TO
select/VB
the/DT
optimal/JJ
number/NN
of/IN
genes/NNS
in/IN
a/DT
cluster/NN
,/,
which/WDT
is/VBZ
based/VBN
on/IN
the/DT
between/IN
and/CC
within/IN
variances/VBZ
of/IN
the/DT
clusters/NNS
form/VBP
the/DT
raw/NN
data/NNS
matrix/VBP
and/CC
its/PRP$
permutation/NN
./.
====================
The/DT
number/NN
of/IN
permutations/NNS
should/MD
be/VB
specified/VBN
in/IN
the/DT
analysis/NN
of/IN
gene/NN
shaving/VBG
for/IN
a/DT
microrray/NN
data/NNS
./.
====================
The/DT
next/JJ
step/NN
is/VBZ
to/TO
remove/VB
the/DT
effect/NN
of/IN
genes/NNS
in/IN
the/DT
optimal/JJ
cluster/NN
,/,
G/NN
say/NN
,/,
from/IN
the/DT
original/JJ
matrix/NN
A/NN
./.
====================
By/IN
computing/VBG
the/DT
average/NN
gene/NN
or/CC
the/DT
vector/NN
of/IN
column/NN
average/NN
for/IN
G/NN
,/,
denoted/VBN
by/IN
G/NN
,/,
we/PRP
can/MD
remove/VB
the/DT
component/NN
that/IN
is/VBZ
correlated/VBN
with/IN
this/DT
average/NN
./.
====================
This/DT
is/VBZ
equivalent/JJ
to/TO
regressing/VBG
each/DT
row/NN
of/IN
A/DT
on/IN
the/DT
average/NN
gene/NN
row/NN
G/NN
,/,
and/CC
replacing/VBG
the/DT
former/JJ
with/IN
the/DT
regression/NN
residuals/NNS
./.
====================
Such/JJ
a/DT
process/NN
is/VBZ
referred/VBN
to/TO
as/IN
orthogonalization/NN
by/IN
Hastie/NN
et/FW
al/JJ
„/CD
from/IN
which/WDT
a/DT
modified/JJ
data/NNS
matrix/VBP
Aortho/NN
is/VBZ
produced/VBN
./.
====================
With/IN
Aortho/NN
,/,
the/DT
whole/JJ
process/NN
is/VBZ
repeated/VBN
of/IN
calculating/JJ
the/DT
leading/VBG
principal/JJ
component/NN
,/,
producing/VBG
another/DT
nested/JJ
sequence/NN
of/IN
shaved/JJ
gene/NN
blocks/VBZ
,/,
applying/VBG
the/DT
Gap/NN
====================
statistic/JJ
to/TO
obtain/VB
the/DT
next/JJ
optimal/JJ
cluster/NN
C/NN
2/CD
,/,
and/CC
====================
orthogonalizing/VBG
the/DT
current/JJ
data/NNS
matrix/VBP
./.
====================
This/DT
sequence/NN
of/IN
operations/NNS
is/VBZ
iterated/VBN
until/IN
L/NN
gene/NN
clusters/NNS
G/NN
,/,
A/DT
,/,
C/NN
l/JJ
====================
are/VBP
found/VBN
,/,
which/WDT
can/MD
be/VB
displayed/VBN
graphically/RB
for/IN
visual/JJ
inspection/NN
./.
====================
‘/CD
Supervised/JJ
shaving/VBG
’/CD
is/VBZ
a/DT
modification/NN
of/IN
gene/NN
shaving/VBG
./.
====================
Full/JJ
or/CC
partial/JJ
supervised/VBD
shaving/VBG
for/IN
class/NN
discrimination/NN
can/MD
be/VB
carried/VBN
out/RP
if/IN
the/DT
information/NN
of/IN
the/DT
column/NN
(/(
sample/NN
)/)
classification/NN
is/VBZ
available/JJ
./.
====================
In/IN
particular/JJ
,/,
an/DT
indicator/NN
vector/NN
with/IN
the/DT
length/NN
of/IN
samples/NNS
is/VBZ
needed/VBN
to/TO
specify/VB
the/DT
sample/NN
classification/NN
./.
====================
When/WRB
fully/RB
supervised/VBD
,/,
the/DT
shaving/VBG
procedure/NN
reduces/VBZ
to/TO
simply/RB
ranking/VBG
the/DT
genes/NNS
./.
====================
Thus/RB
there/EX
is/VBZ
no/DT
role/NN
for/IN
principal/JJ
components/NNS
or/CC
top-down/JJ
shaving/VBG
in/IN
this/DT
case/NN
./.
====================
However/RB
,/,
to/TO
encourage/VB
coherence/NN
within/IN
the/DT
gene/NN
clusters/NNS
,/,
it/PRP
can/MD
be/VB
better/RBR
to/TO
use/VB
a/DT
partially/RB
supervised/VBD
criterion/NN
,/,
which/WDT
does/VBZ
use/NN
principal/JJ
components/NNS
and/CC
top-down/RB
shaving/VBG
./.
====================
In/IN
case/NN
of/IN
Golub/NN
’/CD
s/NNS
acute/JJ
leukemia/NN
data/NNS
,/,
we/PRP
use/VBP
labeled/VBN
38/CD
training/VBG
data/NNS
sets/NNS
samples/NNS
with/IN
ALL/NN
or/CC
AML/NN
and/CC
partially/RB
supervised/VBD
shaving/VBG
method/NN
with/IN
10/CD
times/NNS
permutation/NN
./.
====================
SVMs/NNS
are/VBP
a/DT
relatively/RB
new/JJ
type/NN
of/IN
learning/VBG
algorithm/NN
,/,
originally/RB
introduced/VBN
by/IN
Vapnik/NN
and/CC
co-workers/NNS
(/(
Vapnik/NN
,/,
1998/CD
)/)
and/CC
successively/RB
extended/VBD
by/IN
a/DT
number/NN
of/IN
other/JJ
researchers/NNS
./.
====================
Their/PRP$
remarkably/RB
robust/JJ
performance/NN
with/IN
respect/NN
to/TO
sparse/VB
and/CC
noisy/RB
data/NNS
is/VBZ
making/VBG
them/PRP
the/DT
system/NN
of/IN
choice/NN
in/IN
a/DT
number/NN
of/IN
applications/NNS
from/IN
text/JJ
categorization/NN
to/TO
protein/NN
function/NN
prediction/NN
./.
====================
When/WRB
used/VBN
for/IN
classification/NN
,/,
they/PRP
separate/VBP
a/DT
given/VBN
set/NN
of/IN
binary-labeled/JJ
training/VBG
data/NNS
with/IN
a/DT
hyper-plane/JJ
that/DT
is/VBZ
maximally/RB
distant/JJ
from/IN
them/PRP
(/(
known/VBN
as/IN
‘/CD
the/DT
maximal/JJ
margin/NN
hyper-plane/NN
’/CD
)/)
./.
====================
For/IN
cases/NNS
in/IN
which/WDT
no/DT
linear/JJ
separation/NN
is/VBZ
possible/JJ
,/,
they/PRP
can/MD
work/NN
in/IN
combination/NN
with/IN
the/DT
technique/NN
of/IN
‘/NN
kernels/NNS
’/CD
./.
====================
That/DT
automatically/RB
realizes/VBZ
q/NN
non-linear/JJ
mapping/NN
to/TO
a/DT
feature/NN
space/NN
./.
====================
The/DT
hyper-plane/NN
found/VBN
by/IN
the/DT
SVM/NN
in/IN
feature/NN
space/NN
corresponds/VBZ
to/TO
a/DT
non-linear/JJ
decision/NN
boundary/NN
in/IN
the/DT
input/NN
space/NN
./.
====================
That/DT
is/VBZ
,/,
estimating/VBG
an/DT
SVM/NN
requires/VBZ
specifying/VBG
an/DT
inner-product/NN
kernel/NN
function/NN
,/,
a/DT
measure/JJ
====================
of/IN
similarity/NN
between/IN
two/CD
profile/NN
vectors/NNS
X/NN
'/``
L/NN
-/:
{/CD
x/CC
'/``
i/LS
,/,
K/NN
,/,
x/CC
9/CD
and/CC
X/NN
}/CD
L/NN
-/:
{/CD
x/CC
'/``
i/LS
,/,
K/NN
,/,
x^/CC
}/CD
,/,
where/WRB
x/CC
'/``
L/NN
and/CC
are/VBP
gene/NN
====================
expression/NN
level/NN
of/IN
gene/NN
L/NN
for/IN
samples/NNS
belonging/VBG
to/TO
class/NN
//:
and/CC
//:
Since/IN
there/EX
is/VBZ
no/DT
general/JJ
theory/JJ
for/IN
determining/VBG
the/DT
most/JJS
appropriate/JJ
kernel/NN
for/IN
a/DT
particular/JJ
learning/VBG
problem/NN
,/,
radial/JJ
basis/NN
’/CD
kernel/NN
function/NN
suggested/VBD
that/IN
superior/JJ
to/TO
the/DT
other/JJ
methods/NNS
(/(
Brown/JJ
et/FW
at./IN
,/,
1999/CD
)/)
./.
====================
’/DT
Radial/JJ
basis/NN
’/CD
kernel/NN
function/NN
A/DT
(/(
X/NN
£/CD
,/,
X/NN
'/``
J/NN
=/JJ
exp/NN
(/(
-/:
||/CD
X/NN
'/``
l/NN
-/:
X/NN
'/``
l/NN
II/CD
y/RB
)/)
,/,
where/WRB
y/RB
=/JJ
1/2o/CD
2/CD
is/VBZ
a/DT
user-defined/JJ
width/IN
parameter/NN
./.
====================
Because/IN
of/IN
the/DT
limited/JJ
number/NN
of/IN
training/VBG
examples/NNS
,/,
a/DT
leave-one-out/JJ
cross/JJ
validation/NN
strategy/NN
was/VBD
utilized/VBN
./.
====================
A/DT
pool/NN
of/IN
N/NN
training/VBG
data/NNS
set/VBP
was/VBD
partitioned/VBN
into/IN
two/CD
disjoint/JJ
sets/NNS
./.
====================
The/DT
estimation/NN
set/NN
,/,
A/-1/NN
examples/NNS
,/,
was/VBD
used/VBN
to/TO
determine/VB
the/DT
parameters/NNS
of/IN
an/DT
SVM/NN
,/,
and/CC
the/DT
test/NN
====================
set/NN
,/,
1/CD
example/NN
,/,
was/VBD
used/VBN
to/TO
assess/VB
its/PRP$
generalization/NN
performance/NN
(/(
here/RB
,/,
N=/JJ
38/CD
)/)
./.
====================
The/DT
label/JJ
assigned/VBN
by/IN
a/DT
trained/JJ
SVM/NN
to/TO
a/DT
test/NN
example/NN
can/MD
be/VB
a/DT
true/JJ
positive/JJ
(/(
known/VBN
positive/JJ
test/NN
example/NN
,/,
assigned/VBN
positive/JJ
label/JJ
)/)
,/,
true/JJ
negative/JJ
(/(
negative/JJ
example/NN
,/,
negative/JJ
label/NN
)/)
,/,
false/VBP
positive/JJ
(/(
negative/JJ
example/NN
,/,
positive/JJ
label/JJ
)/)
,/,
or/CC
false/IN
negative/JJ
(/(
positive/JJ
example/NN
,/,
negative/JJ
label/NN
)/)
./.
====================
Golub/NN
’/CD
s/NNS
72/CD
leukemia/NN
samples/NNS
were/VBD
partitioned/VBN
into/IN
estimation/NN
and/CC
test/NN
set/NN
containing/VBG
38/CD
and/CC
34/CD
samples/NNS
,/,
respectively/RB
./.
====================
The/DT
generalization/NN
performance/NN
of/IN
this/DT
’/NN
38/CD
estimation/NN
,/,
34/CD
test/NN
’/CD
partitioning/VBG
is/VBZ
how/WRB
many/JJ
of/IN
the/DT
34/CD
test/NN
examples/NNS
were/VBD
assigned/VBN
to/TO
be/VB
true/JJ
positives/VBZ
or/CC
true/JJ
negatives/NNS
./.
====================
In/IN
order/NN
to/TO
compare/VB
the/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
method/NN
with/IN
other/JJ
gene/NN
selection/NN
techniques/NNS
,/,
other/JJ
methods/NNS
;/:
multiple/JJ
t-test/JJS
and/CC
‘/NN
Prediction/NN
Strength/NN
’/CD
(/(
PS/NN
method/NN
)/)
were/VBD
also/RB
addressed/VBD
./.
====================
Both/DT
of/IN
these/DT
have/VBP
previously/RB
been/VBN
applied/VBN
to/TO
the/DT
gene/NN
selection/NN
method/NN
in/IN
another/DT
published/VBN
study/NN
(/(
Xiong/JJ
et/FW
a/DT
!/JJ
./.
,/,
2001/CD
)/)
./.
====================
The/DT
gene/NN
list/NN
in/IN
table/JJ
1-3/CD
represents/VBZ
the/DT
result/NN
of/IN
each/DT
gene/NN
selection/NN
method/NN
./.
====================
17/CD
genes/NNS
in/IN
two/CD
clusters/NNS
from/IN
‘/CD
supervised/VBD
shaving/VBG
f/IN
(/(
Fig/NN
./.
====================
1/CD
)/)
,/,
and/CC
17/CD
top/NN
ranked/VBD
genes/NNS
in/IN
two/CD
other/JJ
methods/NNS
were/VBD
obtained/VBN
./.
====================
To/TO
ensure/VB
fairness/VBP
in/IN
the/DT
gene/NN
numbers/NNS
,/,
the/DT
same/JJ
numbers/NNS
of/IN
genes/NNS
from/IN
three/CD
methods/NNS
were/VBD
obtained/VBN
./.
====================
Although/IN
the/DT
precise/JJ
composition/NN
of/IN
the/DT
17/CD
genes/NNS
differed/VBD
,/,
each/DT
set/NN
of/IN
genes/NNS
was/VBD
effective/JJ
in/IN
terms/NNS
of/IN
discriminating/VBG
between/IN
different/JJ
tumor/NN
types/NNS
./.
====================
The/DT
small/JJ
overlap/JJ
in/IN
terms/NNS
of/IN
the/DT
specific/JJ
genes/NNS
may/MD
suggest/VB
the/DT
presence/NN
of/IN
many/JJ
gene/NN
subsets/NNS
for/IN
a/DT
given/VBN
cardinality/NN
that/DT
are/VBP
equally/RB
well/RB
generalized/VBN
./.
====================
However/RB
,/,
there/EX
are/VBP
no/DT
common/JJ
genes/NNS
in/IN
the/DT
multiple/JJ
tests/NNS
;/:
the/DT
PS/NN
and/CC
supervised/VBD
shaving/VBG
methods/NNS
./.
====================
Only/RB
small/JJ
overlaps/VBZ
existed/VBD
between/IN
the/DT
two/CD
methods/NNS
./.
====================
It/PRP
should/MD
be/VB
understood/VBN
,/,
that/DT
these/DT
three/CD
methods/NNS
have/VBP
very/RB
different/JJ
basic/JJ
concept/NN
in/IN
analysis/NN
./.
====================
In/IN
other/JJ
words/NNS
,/,
PCA/NN
based/VBN
‘/CD
supervised/VBD
clustering/NN
’/NN
captures/NNS
the/DT
variance/NN
in/IN
a/DT
dataset/NN
in/IN
terms/NNS
of/IN
principle/JJ
components/NNS
,/,
but/CC
other/JJ
two/CD
methods/NNS
are/VBP
not/RB
dependent/JJ
on/IN
variation/NN
but/CC
difference/NN
of/IN
mean/JJ
values/NNS
of/IN
each/DT
samples/NNS
./.
====================
A/DT
union/JJ
set/NN
of/IN
three/CD
gene/NN
lists/NNS
was/VBD
also/RB
made/VBD
,/,
and/CC
trained/VBD
with/IN
a/DT
new/JJ
combined/JJ
data/NNS
matrix/VBP
for/IN
leukemia/NN
cancer/NN
classification/NN
./.
====================
However/RB
,/,
the/DT
result/NN
of/IN
classification/NN
was/VBD
not/RB
as/IN
good/JJ
as/IN
expected/VBN
./.
====================
(/(
Data/NNS
are/VBP
not/RB
shown/VBN
)/)
====================
To/TO
understand/VB
the/DT
scientific/JJ
and/CC
clinical/JJ
relevance/NN
of/IN
====================
our/PRP$
results/NNS
,/,
a/DT
PubMed/JJ
keyword/JJ
search/VBP
was/VBD
conducted/VBN
using/VBG
gene/NN
name/NN
words/NNS
,/,
such/JJ
as/IN
‘/CD
leukemia/NN
’/CD
and/CC
acute/JJ
leukemia/NN
’/CD
./.
====================
The/DT
most/JJS
important/JJ
genes/NNS
found/VBN
have/VBP
also/RB
been/VBN
examined/VBN
in/IN
the/DT
related/JJ
contents/NNS
./.
====================
Table/JJ
1/CD
shows/VBZ
the/DT
gene/NN
list/NN
selected/VBN
by/IN
multiple/JJ
t-tests/NNS
./.
====================
TCF3/NN
(/(
M31523/NN
)/)
,/,
E2A/NN
immunoglobulin/NN
enhancer/NN
binding/NN
factors/NNS
E12/E47/NN
,/,
is/VBZ
associated/VBN
with/IN
childhood/NN
B/NN
cell/NN
acute/JJ
lymphoblastic/JJ
leukemia/NN
./.
====================
The/DT
resulting/VBG
fusion/NN
of/IN
the/DT
5/CD
’/NN
E2A/NN
sequences/NNS
with/IN
the/DT
3/CD
’/NN
portions/NNS
of/IN
other/JJ
genes/NNS
leads/VBZ
to/TO
the/DT
expression/NN
of/IN
two/CD
well-characterized/JJ
fusion/NN
proteins/NNS
,/,
E2A-PBX1/NN
and/CC
E2A-HLF/JJ
./.
====================
Since/IN
the/DT
E2A/NN
,/,
PBX1/NN
and/CC
HLF/NN
proteins/NNS
appears/VBZ
to/TO
function/VB
as/IN
transcription/NN
factors/NNS
,/,
it/PRP
appears/VBZ
likely/JJ
that/IN
the/DT
oncogenic/JJ
fusions/NNS
appear/VBP
to/TO
function/VB
in/IN
development/NN
by/IN
causing/VBG
abnormal/JJ
====================
transcriptional/JJ
regulation/NN
of/IN
key/JJ
target/NN
genes/NNS
(/(
LeBrun/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Fig/NN
./.
====================
2/CD
(/(
a/DT
)/)
shows/VBZ
that/IN
TCF3\s/NN
differentially/RB
expressed/VBN
in/IN
a/DT
training/JJ
sample/NN
(/(
p=0.013/NN
)/)
./.
====================
For/IN
the/DT
genes/NNS
in/IN
Table/JJ
2/CD
,/,
Parisi/NN
et/FW
al/JJ
./.
====================
explored/VBN
new/JJ
therapeutic/JJ
approaches/NNS
to/TO
AML/NN
focused/VBN
on/IN
immune-based/VBN
therapy/NN
through/IN
monoclonal/JJ
antibodies/NNS
that/WDT
target/NN
and/CC
destroy/IN
malignant/JJ
cells/NNS
via/IN
specific/JJ
cell/NN
receptors/NNS
(/(
Parisi/NN
et/FW
aL/FW
,/,
2002/CD
)/)
./.
====================
One/CD
such/JJ
agent/NN
is/VBZ
gemtuzumab/NN
(/(
CAN-676/NN
)/)
,/,
an/DT
agent/NN
that/WDT
targets/VBZ
the/DT
CD33/NN
(/(
M23197/NN
)/)
antigen/NN
on/IN
malignant/JJ
myeloid/JJ
cells/NNS
,/,
and/CC
initial/JJ
studies/NNS
have/VBP
shown/VBN
significant/JJ
anticancer/JJ
activity/NN
./.
====================
In/IN
another/DT
study/NN
(/(
Hamann/NNP
et/FW
al./FW
,/,
2002/CD
)/)
,/,
it/PRP
was/VBD
reported/VBN
that/IN
CD33/NN
is/VBZ
expressed/VBN
by/IN
AML/NN
cell/NN
in/IN
>/JJR
80/CD
%/NN
of/IN
patients/NNS
,/,
but/CC
not/RB
by/IN
normal/JJ
hematipoietic/JJ
stem/NN
cells/NNS
,/,
suggesting/VBG
that/IN
eliminating/VBG
CD33/NN
(/(
+/CC
)/)
cells/NNS
may/MD
be/VB
====================
therapeutically/RB
beneficial/JJ
./.
====================
The/DT
leptin/NN
receptor/NN
gene/NN
-/:
related/JJ
protein/NN
’/CD
(/(
Y12670/NN
)/)
was/VBD
also/RB
found/VBD
in/IN
the/DT
‘/NN
PS/NN
method/NN
’/CD
gene/NN
list/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Recently/RB
,/,
leptin/NN
has/VBZ
been/VBN
shown/VBN
to/TO
play/VB
a/DT
regulatory/JJ
role/NN
for/IN
differentiation/NN
within/IN
the/DT
myeloid/JJ
and/CC
erythroid/JJ
cell/NN
lineage/NN
./.
====================
The/DT
research/NN
on/IN
whether/IN
leptin/NN
plays/VBZ
a/DT
role/NN
in/IN
ALL/NN
shows/VBZ
that/IN
the/DT
leptin/NN
levels/NNS
in/IN
bone/NN
marrow-derived/JJ
plasma/NN
of/IN
children/NN
with/IN
ALL/NN
were/VBD
significantly/RB
lower/JJR
than/IN
in/IN
those/DT
of/IN
healthy/JJ
controls/NNS
(/(
Wex/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
CCND3/NN
(/(
M92287/NN
)/)
,/,
CD79A/NN
(/(
U05259/CD
)/)
,/,
MYB/NN
(/(
U22376/NN
)/)
,/,
HOXA9/NN
(/(
U82759/CD
)/)
and/CC
ZYX/NN
(/(
X95735/NN
)/)
are/VBP
common/JJ
in/IN
two/CD
gene/NN
lists/NNS
,/,
but/CC
are/VBP
not/RB
in/IN
the/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
list/NN
./.
====================
For/IN
those/DT
genes/NNS
in/IN
the/DT
two/CD
common/JJ
methods/NNS
,/,
Sonoki/NNP
et/FW
al/JJ
./.
====================
found/VBN
that/IN
cyclin/NN
D3/NN
(/(
CCND3/NN
)/)
was/VBD
a/DT
target/NN
gene/NN
of/IN
mature/JJ
B/NN
cell/NN
malignancies/NNS
./.
====================
(/(
Sonoki/NN
et/FW
a/DT
!/JJ
./.
,/,
2001/CD
)/)
./.
====================
Another/DT
study/NN
(/(
Krissansen/NNP
et/FW
al/JJ
„/CD
1986/CD
)/)
concluded/VBD
that/IN
glucocorticoids/NNS
cause/VBP
Go/Gi/NNP
arrest/NN
of/IN
lymphoid/JJ
cells/NNS
and/CC
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
to/TO
a/DT
decrease/NN
in/IN
the/DT
abundance/NN
of/IN
the/DT
Gi/NN
progression/NN
factor/NN
,/,
cyclin/NN
D3/NN
,/,
which/WDT
manages/VBZ
regulation/NN
of/IN
the/DT
cell/NN
cycle/NN
./.
====================
The/DT
mRNA/NN
encoding/VBG
cyclin/NN
D3/NN
(/(
CcnD3/NN
mRNA/NN
)/)
was/VBD
rapidly/RB
down/RB
regulated/VBN
when/WRB
dexamethasone/NN
was/VBD
added/VBN
to/TO
P1798/NN
murine/JJ
T/NN
lymphoma/NN
cells/NNS
./.
====================
CD79A/NN
is/VBZ
a/DT
cytoplasmic/JJ
antigen/NN
that/DT
acts/VBZ
as/IN
a/DT
mediator/NN
of/IN
signal/JJ
transduction/NN
from/IN
the/DT
cell/NN
surface/NN
to/TO
the/DT
cytoplasm/NN
in/IN
association/NN
with/IN
CD79b/NN
,/,
and/CC
is/VBZ
expressed/VBN
early/RB
in/IN
B-cell/NN
development/NN
(/(
Lai/NNP
et/FW
a/DT
!/JJ
./.
,/,
2000/CD
)/)
./.
====================
Frater/NN
et/FW
al/JJ
./.
====================
reported/VBN
that/IN
CD79a/NN
has/VBZ
been/VBN
so/RB
clearly/RB
associated/VBN
with/IN
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
by/IN
some/DT
researchers/NNS
that/IN
its/PRP$
expression/NN
in/IN
the/DT
presence/NN
of/IN
blast/NN
markers/NNS
is/VBZ
considered/VBN
indicative/JJ
of/IN
B-ALL/NN
(/(
Frater/NN
et/FW
al/JJ
„/CD
2003/CD
)/)
./.
====================
From/IN
Fig/NN
./.
====================
2/CD
(/(
b/LS
)/)
this/DT
report/NN
could/MD
be/VB
true/JJ
./.
====================
c-myb/NN
is/VBZ
essential/JJ
for/IN
the/DT
development/NN
of/IN
hematopoietic/JJ
cells/NNS
,/,
and/CC
plays/VBZ
a/DT
role/NN
in/IN
proliferation/NN
,/,
anti-apoptosis/JJ
and/CC
differentiation/NN
,/,
c-myb/NN
can/MD
be/VB
activated/VBN
to/TO
transform/VB
myeloid/JJ
cells/NNS
,/,
either/CC
by/IN
over/IN
expression/NN
at/IN
the/DT
transcriptional/JJ
level/NN
or/CC
protein/NN
truncation/NN
,/,
which/WDT
removes/VBZ
sequences/NNS
critical/JJ
for/IN
phosphorylation-induced/JJ
ubiquitinization/NN
and/CC
26S-proteasome/JJ
degradation/NN
(/(
Bies/NNS
et/FW
al./FW
,/,
1997/CD
,/,
1999/CD
)/)
./.
====================
Cytogenetic/JJ
,/,
genetic/JJ
and/CC
functional/JJ
studies/NNS
have/VBP
demonstrated/VBN
a/DT
direct/JJ
link/NN
between/IN
deregulated/VBN
Hoxa9/NN
expression/NN
and/CC
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
./.
====================
The/DT
leukemogenic/JJ
potential/JJ
of/IN
Hoxa9/NN
was/VBD
directly/RB
demonstrated/VBD
by/IN
the/DT
development/NN
of/IN
AML/NN
in/IN
mouse/NN
bone/NN
marrow/NN
transplantation/NN
chimeras/NNS
that/DT
received/VBD
a/DT
graft/NN
====================
of/IN
primitive/JJ
hematopoietic/JJ
cells/NNS
engineered/VBN
by/IN
retroviral/JJ
gene/NN
transfer/NN
to/TO
over/IN
express/VBP
Hoxa9/NN
(/(
Kroon/NN
et/FW
a/DT
!/JJ
„/CD
1998/CD
)/)
./.
====================
In/IN
Table/JJ
3/CD
the/DT
biologically/RB
important/JJ
genes/NNS
obtained/VBN
from/IN
the/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
clustering/NN
method/NN
are/VBP
also/RB
shown/VBN
./.
====================
The/DT
enzyme/NN
myeloperoxidase/NN
(/(
M19507/NN
)/)
is/VBZ
a/DT
well-established/JJ
marker/NN
of/IN
myeloid/JJ
differentiation/NN
./.
====================
Most/JJS
myeloid/JJ
leukemia/NN
expresses/VBZ
MPO/NN
enzyme/NN
activity/NN
at/IN
the/DT
light/JJ
microscopic/JJ
level/NN
,/,
whereas/IN
lymphoid/JJ
leukemia/NN
characteristically/RB
lacks/VBZ
such/JJ
expression/NN
./.
====================
However/RB
,/,
the/DT
diagnostic/JJ
significance/NN
d/FW
MPO/NN
RNA/NN
or/CC
immunohistochemically/RB
detectable/JJ
MPO/NN
protein/NN
expressions/NNS
in/IN
leukemic/JJ
blasts/NNS
is/VBZ
unclear/JJ
./.
====================
It/PRP
has/VBZ
been/VBN
demonstrated/VBN
that/IN
MPO/NN
expression/NN
shows/VBZ
no/DT
significant/JJ
correlation/NN
with/IN
other/JJ
markers/NNS
of/IN
myeloid/JJ
differentiation/NN
(/(
Austin/NN
et/FW
a//FW
„/CD
1998/CD
)/)
./.
====================
However/RB
,/,
Fig/NN
./.
====================
2/CD
(/(
c/NN
)/)
shows/VBZ
MPO/NN
was/VBD
over/IN
expressed/VBN
in/IN
acute/JJ
myeloid/JJ
leukemia/NN
./.
====================
The/DT
chemokine/NN
receptor/NN
CXCR4/NN
(/(
L06797/NN
)/)
is/VBZ
important/JJ
on/IN
acute/JJ
lymphoblastic/JJ
leukemia/NN
,/,
which/WDT
is/VBZ
based/VBN
on/IN
the/DT
research/NN
about/RB
stromal/JJ
cell-derived/JJ
factor/NN
-1/CD
(/(
S£F-7/NN
)/)
inhibitor/NN
(/(
Juarez/NNP
et/FW
a/DT
!/JJ
„/CD
2003/CD
)/)
./.
====================
SDF-1/NN
is/VBZ
a/DT
key/JJ
regulator/NN
of/IN
the/DT
behavior/NN
of/IN
normal/JJ
and/CC
leukemic/JJ
precursor-B/NN
(/(
pre-B/JJ
)/)
cells/NNS
./.
====================
It/PRP
is/VBZ
possible/JJ
that/IN
inhibiting/VBG
SDF-1/NN
driven/VBN
processes/NNS
in/IN
pre-B/JJ
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
may/MD
have/VB
therapeutic/JJ
implications/NNS
./.
====================
SDF-1/NN
and/CC
CXCR4/NN
have/VBP
been/VBN
implicated/VBN
in/IN
numerous/JJ
disease/NN
state/NN
,/,
including/VBG
cancer/NN
metastasis/NN
,/,
cell/NN
infiltration/NN
into/IN
arthritic/JJ
joints/NNS
and/CC
HIV/NN
infection/NN
,/,
as/IN
well/RB
as/IN
survival/NN
and/CC
dissemination/NN
of/IN
leukemic/JJ
blasts/NNS
./.
====================
In/IN
addition/NN
,/,
there/EX
are/VBP
some/DT
remarkable/JJ
points/NNS
in/IN
the/DT
gene/NN
list/NN
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
Some/DT
transcripts/NNS
derived/VBN
from/IN
same/JJ
gene/NN
were/VBD
found/VBN
in/IN
the/DT
list/NN
./.
====================
M28130/CD
and/CC
Y00787/NN
are/VBP
mRNA/NN
transcripted/VBN
from/IN
the/DT
!/NN
L8/NN
(/(
Interleukin/NN
8/CD
)/)
gene/NN
,/,
====================
which/WDT
are/VBP
detected/VBN
in/IN
peripheral/JJ
leukemic/JJ
cells/NNS
obtained/VBN
from/IN
adult/JJ
T-cell/NN
leukemia/NN
patients/NNS
,/,
as/IN
well/RB
as/IN
in/IN
cultured/VBN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
1-infected/JJ
T/NN
cell/NN
lines/NNS
./.
====================
Detection/NN
of/IN
1L-8/NN
and/CC
1L-8R/NN
might/MD
help/VB
to/TO
identify/VB
ALL/NN
types/NNS
,/,
predict/VBP
prognosis/NN
and/CC
the/DT
development/NN
of/IN
CNSL/NN
,/,
which/WDT
is/VBZ
established/VBN
by/IN
Liu/JJ
et/FW
a/DT
!/JJ
./.
,/,
1999/CD
./.
====================
Another/DT
example/NN
is/VBZ
lysozyme/NN
,/,
which/WDT
has/VBZ
J03801/NN
,/,
M19045/NN
and/CC
X14008/CD
for/IN
transcripts/NNS
./.
====================
The/DT
leukemic/JJ
lymphoblasts/NNS
were/VBD
characterized/VBN
by/IN
low/JJ
levels/NNS
of/IN
lysozyme/NN
,/,
as/IN
compared/VBN
to/TO
by/IN
the/DT
leukemic/JJ
myeloblasts/NNS
or/CC
normal/JJ
lymphocytes/NNS
(/(
Ho/NN
et/FW
al./FW
,/,
1984/CD
)/)
./.
====================
It/PRP
is/VBZ
worth/NN
noting/VBG
,/,
1L8/CD
or/CC
Lysozyme/NN
transcripts/NNS
showed/VBD
similar/JJ
expression/NN
patterns/NNS
across/IN
the/DT
leukemia/NN
samples/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
It/PRP
means/NNS
that/DT
this/DT
transcript/NN
expression/NN
is/VBZ
reliable/JJ
and/CC
samples/NNS
are/VBP
subdivided/VBN
./.
====================
Such/JJ
a/DT
phenomenon/NN
was/VBD
not/RB
found/VBN
in/IN
the/DT
other/JJ
gene/NN
list/NN
table/JJ
./.
====================
The/DT
ferritin/JJ
related/JJ
genes/NNS
,/,
FTH1/NN
(/(
L20941/NN
)/)
and/CC
FTL/NN
(/(
M11147/NN
)/)
,/,
are/VBP
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
High/JJ
serum/NN
ferritin/NN
levels/NNS
,/,
without/IN
any/DT
correspondence/NN
to/TO
the/DT
amount/NN
of/IN
total/JJ
body/NN
iron/NN
storage/NN
,/,
have/VBP
been/VBN
found/VBN
in/IN
patients/NNS
with/IN
leukemia/NN
./.
====================
Investigating/VBG
96/CD
adults/NNS
with/IN
different/JJ
types/NNS
of/IN
leukemia/NN
,/,
serum/NN
ferritin/NN
can/MD
be/VB
used/VBN
as/IN
a/DT
tumor/NN
marker/NN
in/IN
myeloid/JJ
./.
====================
So/RB
,/,
the/DT
serum/NN
ferritin/NN
concentration/NN
must/MD
be/VB
valued/VBN
as/IN
a/DT
clinically/RB
useful/JJ
tumor/NN
marker/NN
in/IN
these/DT
types/NNS
of/IN
leukemia/NN
,/,
exhibiting/VBG
a/DT
helpful/JJ
and/CC
simple/JJ
parameter/NN
in/IN
monitoring/VBG
the/DT
activity/NN
of/IN
the/DT
disease/NN
(/(
Aulbert/NNP
et/FW
al./FW
,/,
1985/CD
)/)
./.
====================
Classification/NN
using/VBG
SVM/NN
(/(
Support/NN
Vector/NN
Machine/NN
)/)
As/IN
mentioned/VBN
above/JJ
,/,
bone/NN
marrow/NN
or/CC
peripheral/JJ
blood/NN
samples/NNS
from/IN
72/CD
patients/NNS
with/IN
other/JJ
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
or/CC
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
were/VBD
used/VBN
in/IN
this/DT
study/NN
./.
====================
The/DT
data/NNS
was/VBD
split/NN
into/IN
a/DT
training/JJ
set/NN
consisting/VBG
of/IN
38/CD
samples/NNS
,/,
of/IN
which/WDT
27/CD
were/VBD
ALL/NN
and/CC
====================
11/CD
AML/NN
,/,
and/CC
a/DT
test/NN
set/NN
of/IN
34/CD
samples/NNS
,/,
20/CD
ALL/NN
and/CC
14/CD
AML/NN
./.
====================
The/DT
prediction/NN
on/IN
the/DT
training/VBG
set/NN
using/VBG
SVM/NN
is/VBZ
shown/VBN
in/IN
Table/JJ
4/CD
./.
====================
In/IN
Table/JJ
4/CD
,/,
in/IN
the/DT
top-left/NN
and/CC
bottom-right/CC
are/VBP
correctly/RB
predicted/VBN
leukemia/NN
type/NN
numbers/NNS
and/CC
in/IN
the/DT
top-right/NN
and/CC
bottom-left/CC
are/VBP
the/DT
misclassified/JJ
cases/NNS
,/,
such/JJ
as/IN
ALL/NN
====================
incorrectly/RB
classified/VBN
into/IN
AML/NN
or/CC
the/DT
reverse/JJ
./.
====================
Table/JJ
4/CD
(/(
a/DT
)/)
is/VBZ
the/DT
result/NN
of/IN
prediction/NN
using/VBG
filtering/JJ
processed/VBN
data/NNS
with/IN
3051/CD
genes/NNS
,/,
and/CC
is/VBZ
the/DT
worst/NN
among/IN
the/DT
results/NNS
that/IN
meet/VBP
our/PRP$
expectation/NN
./.
====================
The/DT
result/NN
accuracy/NN
was/VBD
67/CD
%/NN
./.
====================
Tables/NNS
4/CD
(/(
b/LS
)/)
,/,
(/(
c/NN
)/)
and/CC
(/(
d/FW
)/)
represent/VBP
the/DT
results/NNS
of/IN
the/DT
predictions/NNS
using/VBG
the/DT
multiple/JJ
t-test/JJS
,/,
supervised/VBD
shaving/VBG
’/CD
====================
and/CC
PS/NN
method/NN
,/,
respectively/RB
./.
====================
The/DT
prediction/NN
accuracy/NN
with/IN
‘/NN
Supervised/JJ
Shaving/JJ
’/CD
was/VBD
94/CD
%/NN
and/CC
with/IN
the/DT
PS/NN
method/NN
was/VBD
97/CD
%/NN
,/,
which/WDT
were/VBD
better/RBR
than/IN
the/DT
result/NN
of/IN
the/DT
multiple/JJ
t-test/JJS
,/,
which/WDT
was/VBD
85/CD
%/NN
./.
====================
It/PRP
was/VBD
also/RB
found/VBD
that/IN
the/DT
ALL/NN
type/NN
was/VBD
correctly/RB
classified/VBN
in/IN
all/DT
the/DT
methods/NNS
,/,
but/CC
the/DT
AML/NN
type/NN
depended/VBD
on/IN
the/DT
gene/NN
selection/NN
method/NN
./.
====================
AML/NN
patient/NN
number/NN
‘/CD
31/CD
’/CD
in/IN
the/DT
test/NN
data/NNS
was/VBD
misclassified/VBN
as/IN
ALL/NN
in/IN
all/DT
the/DT
SVM/NN
tests/NNS
./.
====================
As/IN
shown/VBN
in/IN
box/NN
plots/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
,/,
AML/NN
patient/NN
sample/NN
number/NN
‘/CD
31/CD
’/CD
tended/VBD
to/TO
a/DT
have/VBP
low/JJ
expression/NN
level/NN
compare/VBP
to/TO
the/DT
other/JJ
AML/NN
patients/NNS
samples/NNS
in/IN
all/DT
three/CD
different/JJ
data/NNS
representation/NN
./.
====================
Therefore/RB
,/,
we/PRP
suppose/VBP
that/DT
this/DT
AML/NN
sample/NN
is/VBZ
not/RB
general/JJ
in/IN
all/DT
AML/NN
or/CC
other/JJ
leukemia/NN
types/NNS
,/,
and/CC
such/JJ
a/DT
sample/JJ
has/VBZ
an/DT
effect/NN
on/IN
the/DT
misclassification/NN
and/CC
incorrect/VB
result/NN
./.
====================
Simultaneously/RB
monitoring/VBG
the/DT
expression/NN
of/IN
thousands/NNS
of/IN
genes/NNS
holds/NNS
great/JJ
promise/VBP
for/IN
better/RBR
understanding/NN
cancer/NN
biology/NN
and/CC
developing/VBG
accurate/JJ
tumor/NN
classification/NN
schemes/VBZ
./.
====================
However/RB
,/,
the/DT
very/RB
large/JJ
amount/NN
of/IN
gene/NN
expression/NN
information/NN
provided/VBD
by/IN
contemporary/JJ
microarray/NN
technology/NN
causes/VBZ
problems/NNS
for/IN
both/DT
basic/JJ
research/NN
and/CC
clinical/JJ
application/NN
./.
====================
The/DT
high/JJ
cost/JJ
of/IN
large-scale/JJ
microarray/NN
experiments/NNS
lead/VBP
to/TO
a/DT
sample/JJ
size/NN
that/DT
is/VBZ
usually/RB
several/JJ
orders/NNS
of/IN
magnitude/NN
smaller/JJR
than/IN
the/DT
number/NN
of/IN
genes/NNS
being/VBG
monitored/VBN
./.
====================
As/IN
a/DT
result/NN
,/,
it/PRP
is/VBZ
mathematically/RB
infeasible/JJ
to/TO
use/VB
all/DT
the/DT
gene/NN
expression/NN
information/NN
to/TO
develop/VB
a/DT
classification/NN
algorithm/NN
for/IN
a/DT
relatively/RB
small/JJ
number/NN
of/IN
tumors/NNS
./.
====================
It/PRP
also/RB
well/RB
documented/VBN
in/IN
the/DT
statistical/JJ
literature/NN
that/DT
too/RB
many/JJ
feature/NN
variable/JJ
genes/NNS
could/MD
harm/VB
the/DT
performance/NN
of/IN
the/DT
classifier/NN
./.
====================
Therefore/RB
,/,
development/NN
of/IN
an/DT
accurate/JJ
tumor/NN
classification/NN
scheme/NN
must/MD
begin/VB
with/IN
selection/NN
of/IN
a/DT
subset/NN
of/IN
the/DT
initially/RB
observed/VBN
genes/NNS
for/IN
tumor/NN
classification/NN
./.
====================
To/TO
determine/VB
the/DT
sets/NNS
of/IN
biologically/RB
meaningful/JJ
genes/NNS
,/,
the/DT
available/JJ
expression/NN
data/NNS
from/IN
6817/CD
genes/NNS
in/IN
47/CD
ALL/NN
and/CC
25/CD
AML/NN
samples/NNS
were/VBD
analyzed/VBN
,/,
and/CC
three/CD
different/JJ
methods/NNS
used/VBN
to/TO
select/VB
subsets/NNS
of/IN
genes/NNS
./.
====================
The/DT
PCA/NN
based/VBN
supervised/VBD
shaving/VBG
’/CD
method/NN
was/VBD
identified/VBN
to/TO
produce/VB
subsets/NNS
of/IN
genes/NNS
that/WDT
were/VBD
more/RBR
leukemia/NN
related/JJ
than/IN
other/JJ
methods/NNS
,/,
and/CC
the/DT
expression/NN
pattern/NN
of/IN
some/DT
genes/NNS
were/VBD
correlated/VBN
to/TO
each/DT
other/JJ
because/IN
the/DT
transcripts/NNS
came/VBD
from/IN
the/DT
same/JJ
gene/NN
(/(
Fig/NN
./.
====================
2/CD
(/(
d/FW
)/)
,/,
(/(
e/NN
)/)
)/)
./.
====================
The/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
method/NN
uses/VBZ
information/NN
about/IN
the/DT
columns/NNS
to/TO
‘/CD
supervise/VBP
’/CD
the/DT
shaving/VBG
of/IN
rows/NNS
./.
====================
In/IN
this/DT
case/NN
,/,
leukemia/NN
type/NN
class/NN
labels/NNS
were/VBD
used/VBN
,/,
and/CC
supervised/VBD
shaving/VBG
maximizes/VBZ
a/DT
weighted/JJ
combination/NN
of/IN
the/DT
column/NN
variance/NN
====================
using/VBG
the/DT
information/NN
./.
====================
So/RB
,/,
most/JJS
genes/NNS
have/VBP
a/DT
higher/JJR
variance/NN
between/IN
two/CD
samples/NNS
than/IN
other/JJ
subsets/NNS
of/IN
genes/NNS
./.
====================
Because/IN
the/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
method/NN
====================
identifies/VBZ
subsets/NNS
of/IN
genes/NNS
with/IN
coherent/JJ
expression/NN
patterns/NNS
and/CC
a/DT
large/JJ
variance/NN
across/IN
samples/NNS
,/,
it/PRP
may/MD
not/RB
find/VB
non-coherent/JJ
genes/NNS
,/,
but/CC
that/IN
have/VBP
a/DT
significant/JJ
difference/NN
between/IN
two/CD
samples/NNS
./.
====================
However/RB
,/,
most/JJS
genes/NNS
are/VBP
very/RB
important/JJ
from/IN
a/DT
biological/JJ
and/CC
clinical/JJ
point/NN
of/IN
view/NN
,/,
and/CC
show/VBP
good/JJ
performance/NN
in/IN
classification/NN
./.
====================
In/IN
the/DT
same/JJ
manner/NN
,/,
the/DT
PS/NN
method/NN
also/RB
produces/VBZ
high/JJ
accuracy/NN
in/IN
classification/NN
,/,
but/CC
a/DT
genes/NNS
’/CD
composition/NN
is/VBZ
dissimilar/JJ
to/TO
that/DT
of/IN
the/DT
supervised/VBN
shaving/VBG
gene/NN
,/,
and/CC
some/DT
ideas/IN
may/MD
be/VB
suggested/VBN
by/IN
such/JJ
a/DT
different/JJ
gene/NN
selection/NN
method/NN
./.
====================
First/RB
,/,
for/IN
investigations/NNS
involving/VBG
a/DT
large/JJ
number/NN
of/IN
observed/VBN
variables/NNS
,/,
it/PRP
is/VBZ
often/RB
useful/JJ
to/TO
simplify/VB
the/DT
analysis/NN
by/IN
considering/VBG
a/DT
smaller/JJR
number/NN
of/IN
linear/JJ
combinations/NNS
of/IN
the/DT
original/JJ
variable/JJ
./.
====================
In/IN
this/DT
case/NN
,/,
gene/NN
expression/NN
data/NNS
consist/VBP
of/IN
a/DT
number/NN
of/IN
microarray/NN
experiment/NN
(/(
samples/NNS
)/)
in/IN
thousands/NNS
of/IN
genes/NNS
./.
====================
To/TO
identify/VB
differentially/RB
expressed/VBN
genes/NNS
,/,
the/DT
multiple/JJ
t-test/JJS
and/CC
PS/NN
method/NN
frequently/RB
reduce/VBP
the/DT
intensity/NN
from/IN
all/DT
gene/NN
expressions/NNS
to/TO
a/DT
single/JJ
mean/JJ
value/NN
that/IN
corresponds/VBZ
to/TO
a/DT
sample/JJ
group/NN
./.
====================
This/DT
process/NN
may/MD
be/VB
inadequate/JJ
to/TO
understand/VB
data/NNS
representation/NN
and/CC
depends/VBZ
on/IN
the/DT
data/NNS
itself/PRP
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
PCA/NN
based/VBN
methods/NNS
reduce/VBP
the/DT
dimensionality/NN
of/IN
a/DT
data/NNS
set/VBP
,/,
while/IN
retaining/VBG
as/IN
much/RB
information/NN
as/IN
possible/JJ
./.
====================
So/RB
,/,
the/DT
result/NN
may/MD
be/VB
affected/VBN
by/IN
the/DT
difference/NN
of/IN
cell/NN
lines/NNS
in/IN
the/DT
same/JJ
sample/NN
group/NN
./.
====================
Second/JJ
,/,
deciding/VBG
on/IN
the/DT
number/NN
of/IN
informative/JJ
genes/NNS
is/VBZ
a/DT
problem/NN
./.
====================
All/DT
of/IN
the/DT
three/CD
compared/VBN
methods/NNS
have/VBP
this/DT
problem/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
‘/NN
supervised/VBD
shaving/VBG
’/CD
method/NN
,/,
the/DT
cluster/NN
number/NN
is/VBZ
a/DT
case/NN
in/IN
point/NN
./.
====================
In/IN
this/DT
report/NN
,/,
the/DT
cluster/NN
number/NN
was/VBD
fixed/JJ
as/IN
two/CD
,/,
and/CC
corresponded/VBD
to/TO
17/CD
genes/NNS
./.
====================
However/RB
,/,
the/DT
investigator/NN
should/MD
decide/VB
the/DT
cut-off/JJ
value/NN
for/IN
selecting/VBG
genes/NNS
in/IN
the/DT
multiple/JJ
t-test/JJS
and/CC
PS/NN
method/NN
./.
====================
In/IN
order/NN
to/TO
do/VBP
justice/RB
to/TO
the/DT
gene/NN
number/NN
,/,
other/JJ
methods/NNS
also/RB
produce/VBP
the/DT
17/CD
top/NN
ranked/VBD
genes/NNS
./.
====================
However/RB
,/,
only/RB
2/CD
or/CC
3/CD
genes/NNS
can/MD
achieve/VB
more/RBR
than/IN
90/CD
%/NN
accuracy/NN
of/IN
classification/NN
./.
====================
This/DT
result/NN
implies/VBZ
that/IN
a/DT
small/JJ
number/NN
of/IN
selected/VBN
genes/NNS
may/MD
be/VB
used/VBN
as/IN
biomarkers/NNS
for/IN
tumor/NN
classification/NN
,/,
or/CC
may/MD
have/VB
some/DT
relevance/NN
in/IN
tumor/NN
development/NN
,/,
and/CC
serve/VBP
as/IN
a/DT
potential/JJ
drug/NN
target/NN
(/(
Xiong/JJ
et/FW
al/JJ
,/,
,/,
2001/CD
)/)
./.
====================
In/IN
conclusion/NN
,/,
there/EX
is/VBZ
no/DT
general/JJ
method/NN
to/TO
select/VB
the/DT
right/JJ
informative/JJ
gene/NN
,/,
but/CC
the/DT
PCA/NN
based/VBN
method/NN
‘/CD
supervised/VBD
shaving/VBG
’/CD
gives/VBZ
biologically/RB
and/CC
clinically/RB
meaningful/JJ
genes/NNS
./.
====================
There/EX
is/VBZ
no/DT
single/JJ
best/JJS
procedure/NN
for/IN
selecting/VBG
an/DT
optimal/JJ
subset/NN
of/IN
genes/NNS
./.
====================
It/PRP
was/VBD
not/RB
the/DT
purpose/NN
of/IN
this/DT
paper/NN
to/TO
find/VB
the/DT
optimum/JJ
methods/NNS
for/IN
gene/NN
selection/NN
,/,
but/CC
rather/RB
to/TO
illustrate/VB
how/WRB
gene/NN
selection/NN
can/MD
be/VB
useful/JJ
to/TO
cancer/NN
classification/NN
using/VBG
microarray/NN
gene/NN
expression/NN
data/NNS
classification/NN
./.
====================
In/IN
this/DT
report/NN
,/,
three/CD
statistical/JJ
procedures/NNS
were/VBD
compared/VBN
for/IN
their/PRP$
accuracy/NN
of/IN
cancer/NN
classification/NN
:/:
multiple/JJ
t/NN
tests/NNS
,/,
the/DT
PS/NN
statistic/JJ
====================
suggested/VBD
by/IN
Golub/NN
et/FW
al/JJ
./.
====================
and/CC
supervised/VBD
shaving/VBG
’/CD
./.
====================
The/DT
result/NN
indicates/VBZ
the/DT
PS/NN
method/NN
and/CC
‘/NN
supervised/VBD
shaving/VBG
’/CD
methods/NNS
performed/VBN
similarly/RB
,/,
and/CC
both/CC
methods/NNS
performed/VBN
better/RBR
than/IN
the/DT
t/NN
statistics/NNS
./.
====================
However/RB
,/,
the/DT
supervised/VBN
shaving/VBG
’/CD
method/NN
demands/VBZ
much/RB
more/RBR
====================
computational/JJ
time/NN
than/IN
the/DT
PS/NN
method/NN
./.
====================
An/DT
attempt/NN
to/TO
use/VB
the/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
clustering/NN
algorithm/NN
to/TO
select/VB
informative/JJ
genes/NNS
suggests/VBZ
the/DT
use/NN
of/IN
the/DT
clustering/NN
method/NN
as/IN
a/DT
gene/NN
selection/NN
method/NN
./.
====================
The/DT
level/NN
of/IN
expressions/NNS
of/IN
sets/NNS
(/(
clusters/NNS
)/)
of/IN
genes/NNS
across/IN
samples/NNS
correlate/VBP
./.
====================
As/IN
a/DT
result/NN
,/,
it/PRP
is/VBZ
likely/JJ
that/IN
a/DT
smaller/JJR
number/NN
without/IN
significant/JJ
loss/NN
of/IN
information/NN
can/MD
capture/VB
the/DT
information/NN
contained/VBD
in/IN
all/DT
large/JJ
numbers/NNS
of/IN
genes/NNS
./.
====================
This/DT
is/VBZ
a/DT
direct/JJ
result/NN
of/IN
the/DT
fact/NN
that/IN
sets/NNS
of/IN
genes/NNS
are/VBP
similarly/RB
regulated/VBN
and/CC
,/,
hence/RB
,/,
play/VBP
a/DT
similar/JJ
role/NN
in/IN
cancer/NN
classification/NN
./.
====================
It/PRP
is/VBZ
known/VBN
from/IN
pattern/NN
recognition/NN
theory/JJ
that/DT
a/DT
good/JJ
feature/NN
subset/NN
is/VBZ
one/CD
that/DT
contains/VBZ
features/NNS
highly/RB
correlated/VBD
with/IN
the/DT
class/NN
,/,
yet/RB
uncorrelated/JJ
with/IN
each/DT
other/JJ
./.
====================
In/IN
this/DT
report/NN
,/,
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
a/DT
number/NN
of/IN
gene/NN
clusters/NNS
are/VBP
obtained/VBN
from/IN
the/DT
‘/NN
supervised/VBD
shaving/VBG
’/CD
method/NN
./.
====================
The/DT
expression/NN
levels/NNS
of/IN
genes/NNS
within/IN
the/DT
same/JJ
cluster/NN
have/VBP
high/JJ
correlation/NN
,/,
and/CC
the/DT
expression/NN
levels/NNS
of/IN
genes/NNS
in/IN
different/JJ
clusters/NNS
have/VBP
low/JJ
correlation/NN
./.
====================
It/PRP
is/VBZ
speculated/VBN
that/DT
the/DT
genes/NNS
within/IN
a/DT
cluster/NN
lie/VBP
in/IN
a/DT
single/JJ
or/CC
co-regulated/JJ
pathway/NN
,/,
and/CC
genes/NNS
in/IN
different/JJ
clusters/NNS
lie/VBP
in/IN
different/JJ
pathways/NNS
or/CC
in/IN
pathways/NNS
that/WDT
are/VBP
not/RB
co-regulated/VBN
./.
====================
So/RB
,/,
the/DT
progress/NN
of/IN
a/DT
clustering/NN
method/NN
to/TO
select/VB
informative/JJ
coherent/JJ
genes/NNS
is/VBZ
needed/VBN
for/IN
cancer/NN
classifications/NNS
./.
====================
